Price
CHART BY
Frequently asked questions
What is Coherus's market capitalization?
The market capitalization of Coherus is $102.31M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Coherus?
Coherus's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.377. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Coherus's stock?
Currently, 6 analysts cover Coherus's stock, with a consensus target price of $4.70. Analyst ratings provide insights into the stock's expected performance.
What is Coherus's revenue over the trailing twelve months?
Over the trailing twelve months, Coherus reported a revenue of $142.77M.
What is the EBITDA for Coherus?
Coherus's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$128.24M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Coherus?
Coherus has a free cash flow of -$105.87M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Coherus have, and what sector and industry does it belong to?
Coherus employs approximately 228 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Coherus's shares?
The free float of Coherus is 105.68M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $102.31M
- EPS (TTM)
- -$1.377
- Free Float
- 105.68M
- Revenue (TTM)
- $142.77M
- EBITDA (TTM)
- -$128.24M
- Free Cashflow (TTM)
- -$105.87M
Pricing
- 1D span
- $0.849$0.888
- 52W span
- $0.66$2.43
Analyst Ratings
The price target is $4.70 and the stock is covered by 6 analysts.
Buy
3
Hold
3
Sell
0
Information
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
- Employees
- 228
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US19249H1032
- Primary Ticker
- CHRS
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet